SAILING INTO THE FUTURE. TOGETHER It’s a great emotion for IBSA, skipper Alberto Bona and the whole team of the international project Sailing into the Future. Together for this occasion, which officially kicks off the countdown to the Route du Rhum 2022, starting on November 6 from Saint-Malo. One month after the technical launch, Alberto … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “India Over The Counter Drug Market, By Product Type, By Route of Administration, By Dosage Form, By Distribution Channel, By Region, Competition, Forecast & Opportunities, 2018-2028F” report has been added to ResearchAndMarkets.com’s offering. India Over the Counter (OTC) Drug market stood at USD4666.15 Million in 2022 and is expected to grow at a … [Read more…]
Combined Company Dedicated to Developing and Delivering Novel Technologies and Solutions to Improve the Lives of Patients with Cardiac Arrhythmias Medtech Veteran David Jenkins to Lead Merged Company CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) announces it has entered into an Agreement and Plan of Merger (the “Definitive … [Read more…]
Updated qPCR system now includes integrated software to support growing test menus for clinical laboratories and assay developers CARLSBAD, Calif.–(BUSINESS WIRE)–Thermo Fisher Scientific has certified the Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System* to meet new In Vitro Medical Devices Regulation (IVDR) requirements. The updated system now includes new, complementary Applied Biosystems Diomni … [Read more…]
Additional positive TG6002 Phase I data show that the oncolytic virus is able to reach the tumor, replicate and express its payload in all patients when administered intravenously STRASBOURG, France–(BUSINESS WIRE)–$TNG–Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces positive confirmatory data from the … [Read more…]
Debt restructuring supports corporate priorities by realigning debt obligations with expected development and commercialization timelines Execution of the definitive amendment is expected in Q4 2022 after finalization of legal documentation PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$NBTX #NBTXNews–Regulatory News: NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to … [Read more…]
MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion on Sensorion’s application … [Read more…]
Early signals of clinical activity observed in second dosing cohort with one partial response TAC01-HER2 was safe and well-tolerated in the first two dosing cohorts of TACTIC-2 Phase 1/2 clinical trial AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural … [Read more…]
Celregen Obtains the Exclusive Rights to Develop, Manufacturing and Commercialize CLS001 in Greater China Region; Cellusion Retains Other Regional Rights. The Deal is Worth up to over $100 Million, including Upfront, Development and Sales Milestone Payments, and Tiered Royalties. TOKYO & HANGZHOU, China & SHANGHAI–(BUSINESS WIRE)–Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., “Cellusion”), a Japanese … [Read more…]
– Remarkable North Star Ambulatory Assessment scale (NSAA) improvements relative to BMD natural history trajectories – – Significant decrease in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers strongly associated with muscle damage caused by BMD – – EDG-5506 continues to be well-tolerated with no serious adverse events observed – – … [Read more…]
